1. Nosocomial infectious complications in patients with urological malignancies
- Author
-
N. V. Dmitrieva, V. V. Aginova, I. N. Petukhova, E. N. Sokolova, S. A. Dyakova, Z. V. Grigoryevskaya, and E. N. Kulaga
- Subjects
Urology ,Antibiotic sensitivity ,urological cancer patient ,Tigecycline ,Microbiology ,03 medical and health sciences ,chemistry.chemical_compound ,nosocomial infection pathogens ,0302 clinical medicine ,Antibiotic resistance ,medicine ,polycyclic compounds ,Radiology, Nuclear Medicine and imaging ,030304 developmental biology ,0303 health sciences ,biology ,taxonomic structure ,business.industry ,Teicoplanin ,biochemical phenomena, metabolism, and nutrition ,biology.organism_classification ,bacterial infections and mycoses ,antibiotic sensitivity ,Acinetobacter baumannii ,Oncology ,chemistry ,Nephrology ,030220 oncology & carcinogenesis ,Linezolid ,Vancomycin ,bacteria ,Medicine ,Surgery ,Daptomycin ,eskape group ,business ,medicine.drug - Abstract
The objective of the study was to analyze the taxonomic structure of urinary infection pathogens and determine the susceptibility of ESKAPE group microorganisms (Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterococcus spp.) isolated from cancer patients with nosocomial infections in 2018—2020 to antimicrobials.Materials and methods. 413 (71.9 %) strains of ESKAPE group bacteria from 228 patients were studied. Microorganisms were identified and antibiotic resistance was determined using Vitek-2 System (France) and MicroScan WalkAway (Germany / USA) analyzers.Results and conclusion. All gram-positive microorganisms were highly sensitive to vancomycin and teicoplanin, linezolid, tigecycline, and daptomycin, which can be used in the treatment if clinical indications are seen. Among gram-negative bacteria, the percentage of ESBL producers was 60—70 %, the percentage of carbapenem-resistant bacteria was minimalfor E. coli, rnmpared to the rest - 40—50 %, demonstrating the need to limit the use of carbapenems in the clinic.
- Published
- 2021